Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: Transgenic swine: expression of human CD39 protects against myocardial injury
Author: Wheeler, D.
Joseph, M.
Mahamud, S.
Aurand, W.
Mohler, P.
Pompili, V.
Dwyer, K.
Nottle, M.
Harrison, S.
d'Apice, A.
Robson, S.
Cowan, P.
Gumina, R.
Citation: Journal of Molecular and Cellular Cardiology, 2012; 52(5):958-961
Publisher: Academic Press Ltd
Issue Date: 2012
ISSN: 0022-2828
Statement of
Debra G. Wheeler, Matthew E. Joseph, Shouvik D. Mahamud, William L. Aurand, Peter J. Mohler, Vincent J. Pompili, Karen M. Dwyer, Mark B. Nottle, Sharon J. Harrison, Anthony J.F. d'Apice, Simon C. Robson, Peter J. Cowan and Richard J. Gumina
Abstract: <h4>Unlabelled</h4>CD39 (ectonucleoside triphosphate diphosphohydrolase-1; ENTPD-1) rapidly hydrolyzes ATP and ADP to AMP; AMP is hydrolyzed by ecto-5'-nucleotidase (CD73) to adenosine, an anti-thrombotic and cardiovascular protective mediator. While expression of human CD39 in a murine model of myocardial ischemia/reperfusion (I/R) injury confers cardiac protection, the translational therapeutic potential of these findings requires further testing in a large animal model. To determine if transgenic expression of CD39 reduces infarct size in a swine model of myocardial ischemia/reperfusion injury, transgenic pigs expressing human CD39 (hCD39) were generated via somatic cell nuclear transfer and characterized. Expression of hC39 in cardiac tissue was confirmed by immunoblot and immunohistochemistry. Myocardial I/R injury was induced by intracoronary balloon inflation in the left anterior descending (LAD) artery for 60 min followed by 3 hours of reperfusion. The ischemic area was delineated by perfusion with 5% phthalo blue and the myocardial infarct size was determined by triphenyl tetrazolium chloride (TTC) staining. During ischemia, the rate-pressure product was significantly lower in control versus hCD39-Tg swine. Following reperfusion, compared to littermate control swine, hCD39-Tg animals displayed a significant reduction in infarct size (hCD39-Tg: 17.2 ± 4.3% vs.<h4>Control</h4>44.7 ± 5.2%, P=0.0025). Our findings demonstrate for the first time that the findings in transgenic mouse models translate to large animal transgenic models and validate the potential to translate CD39 into the clinical arena to attenuate human myocardial ischemia/reperfusion injury.
Keywords: Coronary Vessels; Heart Ventricles; Animals; Animals, Genetically Modified; Swine; Humans; Myocardial Reperfusion Injury; Ischemia; Apyrase; Recombinant Proteins; Antigens, CD; Blood Pressure; Heart Rate; Promoter Regions, Genetic
Rights: © 2012 Elsevier Ltd. All rights reserved.
RMID: 0020118374
DOI: 10.1016/j.yjmcc.2012.01.002
Appears in Collections:Obstetrics and Gynaecology publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.